NWBO Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 21:59):

Stats
Dagens volum	1.33M
Gjennomsnittsvolum	1.73M
Markedsverdi	562.62M
EPS	$0 ( 2024-02-29 )
Neste inntjeningsdato	( $0 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-7.88
ATR14	$0.00200 (0.42%)

Insider Trading

Date	Person	Action	Amount	type
2023-11-16	Malik Navid	Buy	125 000	Common Stock
2023-11-17	Malik Navid	Buy	150 000	Common Stock
2023-11-17	Malik Navid	Buy	295 000	Common Stock
2023-04-03	Bosch Marnix L	Buy	119 355	Common Stock
2023-04-04	Boynton Alton L	Sell	6 794 191	STOCK OPTIONS

INSIDER POWER
-81.43
Last 96 transactions
Buy: 331 589 317 \| Sell: 61 146 214

Volum Korrelasjon

Lang: -0.03 (neutral)

Kort: 0.09 (neutral)

Signal:(53.88) Neutral

Northwest Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Northwest Korrelasjon - Valuta/Råvare

0.44
( neutral )

0.48
( neutral )

0.00
( neutral )

-0.51
( weak negative )

Northwest Økonomi

Annual	2023
Omsetning:	$1.93M
Bruttogevinst:	$199 000 (10.30 %)
EPS:	$-0.0559

FY	2023
Omsetning:	$1.93M
Bruttogevinst:	$199 000 (10.30 %)
EPS:	$-0.0559

FY	2022
Omsetning:	$1.68M
Bruttogevinst:	$135 000 (8.02 %)
EPS:	$-0.130

FY	2021
Omsetning:	$1.01M
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$0.210

Financial Reports:

No articles found.

Northwest

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.